ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2091

Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus

Goh Murayama1, Asako Chiba2, Atsushi Nomura3, Hirofumi Amano1, Ken Yamaji1, Naoto Tamura1 and Sachiko Miyake4,5, 1Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, 3JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, Tokyo, Japan, 4Division of Immunology/NCNP, Natl Institute of Neuroscience, Kodaira Tokyo, Japan, 5Immunology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: innate immunity, Nephritis and treatment, SLE, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain: Vα7.2-Jα33 in humans and Vα19-Jα33 in mice. Previously, we reported that MAIT cells are activated in patients with systemic lupus erythematosus (SLE) and that the activation state of these cells correlated with disease activity. By using MR1 deficient mice lacking MAIT cells, we revealed that MAIT cells contribute to the disease severity of lupus in FcγRIIB-/- Yaa mice. In this study, we asked how MAIT cells are involved in the pathogenesis in this lupus model and explored their potential as a therapeutic target for lupus. We also investigated whether MAIT cells infiltrate in the nephritic kidneys of lupus patients.

Methods:

FcγRIIB-/- Yaa mice were crossed to MR1 deficient mice lacking MAIT cells, and disease progression was compared between MR1-/- and MR1+/+ FcγRIIB-/- Yaa mice. The levels of serum anti-dsDNA antibody and urinary albumin were measured. The severity of nephritis was assessed histologically. T and B cell subsets in the spleen and kidneys at 2 months of age were analyzed by using flow cytometry. FcγRIIb-/- Yaa mice were treated with a suppressive MR1 ligand(MR1L) orally three times weekly for 4 weeks starting at 4 weeks of age. Infiltration of MAIT cells was assessed in kidney biopsy specimens from lupus patients using a confocal microscope.

Results:

MAIT cell deficiency improved the disease course of lupus in FcγRIIb-/- Yaa mice as shown by the increased survival rate, reduced serum anti-dsDNA antibody levels, glomerulonephritis scores and IgG and C3 deposition in glomeruli in MR1-/- FcγRIIB-/- Yaa mice. MAIT cells enhanced germinal center reaction which was accompanied by the increase of T follicular helper cells, germinal center B and plasma cells and the reduction of T regulatory and T follicular regulatory cells. The presence of MAIT cells enhanced cytokine producing capacity of T and innate-T cells in the spleen and kidneys. Activated MAIT cells were accumulated in the kidneys and produced inflammatory cytokines. Administration of MR1L decreased serum anti-ds DNA antibody levels and reduced germinal center B and plasma cells. The deposition of IgG and C3 in the glomeruli was also reduce in FcγRIIb-/- Yaa mice treated with MR1L. MAIT cells were accumulated in the nephritic kidneys of lupus patients.

Conclusion:

MAIT cells exacerbated the disease severity of lupus by enhancing autoantibody production and tissue inflammation in FcγRIIb-/- Yaa mice. MAIT cells were found in the nephritic kidneys of lupus patients, suggesting these cells may also contribute to lupus pathogenesis in human patients. As administration of MR1L suppressed the disease course of lupus, MAIT cells hold potential as a new therapeutic target for SLE.


Disclosure: G. Murayama, None; A. Chiba, CeUGAI PHARMACEUTICAL CO., LTD, 8; A. Nomura, None; H. Amano, None; K. Yamaji, None; N. Tamura, Chugai Parmaceutical Co., LTD, 2,Astellas Pharma Inc., 2,ASAHI KASEI MEDICAL, 2,Sanofi K.K., 8,Bristol-Myers Squibb, 8; S. Miyake, TAIHO PHARMACEUTICAL CO., LTD., 5,Chugai Parmaceutical Co., LTD, 8,Astellas Pharma Inc., 8,Bristol-Myers Squibb, 8,Sanofi K.K., 8,Pfizer, Inc., 8,AYUMI Pharmaceutical Co., LTD, 8.

To cite this abstract in AMA style:

Murayama G, Chiba A, Nomura A, Amano H, Yamaji K, Tamura N, Miyake S. Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/mucosal-associated-invariant-t-mait-cells-as-a-potential-therapeutic-target-for-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mucosal-associated-invariant-t-mait-cells-as-a-potential-therapeutic-target-for-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology